X4 Pharmaceuticals (XFOR) Cash from Operations (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Cash from Operations of 15518000.0 for Q4 2025, up 44.18% on a QoQ basis from 27800000.0 in Q3 2025, and up 52.97% year-over-year from 10144563.52 in Q4 2024.
X4 Pharmaceuticals (XFOR) Cash from Operations (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Cash from Operations history runs 9 years deep, the most recent figure standing at 15518000.0 for Q4 2025.
- Quarterly Cash from Operations rose 52.97% year-over-year to 15518000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 85618000.0 (up 47.96% YoY) and the FY2025 annual result came in at 85618000.0, up 34.59% from the prior year.
- Cash from Operations was 15518000.0 for Q4 2025 at X4 Pharmaceuticals, up from 27800000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 12368000.0 in Q1 2025 and bottomed at 68800000.0 in Q3 2023.
- A 5-year average of 28455400.0 and a median of 23370500.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations plunged 256.37% — and 2025, when it jumped 63.19%.
- X4 Pharmaceuticals' Cash from Operations stood at 19053000.0 in 2021, then declined by 0.21% to 19093000.0 in 2022, then tumbled by 45.33% to 27747000.0 in 2023, then dropped by 18.91% to 32995000.0 in 2024, then jumped by 52.97% to 15518000.0 in 2025.
- Business Quant data shows XFOR's Cash from Operations at 15518000.0 in Q4 2025, 27800000.0 in Q3 2025, and 29932000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 70.50 Mn |
| 10 | X4 Pharmaceuticals | 167.86 Mn | -49.18 Mn | 2.20 Mn | -15.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.52 Mn |
| Dec 31, 2025 | -15.52 Mn |
| Sep 30, 2025 | -27.80 Mn |
| Sep 30, 2025 | -27.80 Mn |
| Jun 30, 2025 | -29.93 Mn |
| Jun 30, 2025 | -29.93 Mn |
| Mar 31, 2025 | -12.37 Mn |
| Mar 31, 2025 | -12.37 Mn |
| Dec 31, 2024 | -33.00 Mn |
| Dec 31, 2024 | -33.00 Mn |
| Sep 30, 2024 | -34.03 Mn |
| Sep 30, 2024 | -34.03 Mn |
| Jun 30, 2024 | -63.90 Mn |
| Jun 30, 2024 | -63.90 Mn |
| Mar 31, 2024 | -33.60 Mn |
| Mar 31, 2024 | -33.60 Mn |
| Dec 31, 2023 | -27.75 Mn |
| Dec 31, 2023 | -27.75 Mn |
| Sep 30, 2023 | -68.80 Mn |
| Sep 30, 2023 | -68.80 Mn |